Viking Therapeutics heads into the back half of July with a stock down 11% on the week, a short base stubbornly above 20% of the float, and options traders who look distinctly unconcerned about further downside.
The short position is the defining feature of the setup. Short interest runs at 20.6% of the free float — roughly 23.3 million shares — and has barely moved over the past week, down less than 0.3%. Over the past month it has crept up 3.4%. That is a heavy structural position for a clinical-stage biotech. Days to cover sits at 9.84 per FINRA data, meaning shorts would need nearly two weeks of average volume to unwind. Yet the lending market tells a different story: availability is at 223% — more than two shares available for every one already borrowed — and cost to borrow has slid 15% this week to just 0.40%. Shorts are not scrambling. The borrow is cheap and there is plenty of it, leaving no obvious mechanical pressure to force a cover. Availability hit a 52-week trough of 7.6% at some point in the past year, so the current reading represents a genuinely loose lending environment by VKTX standards.
Options positioning is where the tension sharpens. The put/call ratio dropped to 0.20 on Tuesday — actually below its 20-day average of 0.22 and close to the 52-week low of 0.164. That is the opposite of fear: call buyers are dominating the options market even as the stock falls. The z-score of -0.82 confirms that hedging demand is below average, not elevated. The 52-week high on the PCR was 0.543, so the market has been far more defensively positioned before. Right now options traders appear to be leaning toward a recovery, not bracing for more pain. The contrast with the 20%-plus short base is the central tension: a crowded short book sitting alongside a call-heavy options market.
The Street remains firmly in the bull camp, though the most recent analyst data is from late May, worth noting when the stock is trading at $33.86 and the consensus price target is $92.58. That gap — implying around 173% upside — reflects targets that were set when the stock was trading materially higher. The most recently active firms held Buy or Overweight ratings; Lake Street initiated coverage with an $89 target in late May, and BTIG has maintained a $125 target. The bull case centers on VK2735, VKTX's GLP-1/GIP dual agonist, and the Phase 3 oral data readout that management has flagged as the key upcoming catalyst. Bears point to clinical execution risk, regulatory complexity in an increasingly crowded weight-loss market, and the absence of any revenue. The ORTEX short score sits at 73.3 — a high reading, ranking in just the 9th percentile for short-score favorability — while the EPS surprise factor scores in the 87th percentile, reflecting a consistent record of beating estimates even in the absence of commercial revenue.
Institutional holders offer a nuanced picture. BlackRock added 351,000 shares as of June 30, and State Street added 1.23 million shares in the same period. American Century built a position of 1.77 million net new shares as of May. Two Sigma added nearly 2 million shares. The accumulation from passive and systematic managers contrasts with the heavy short book — the shorts are not being crowded out by institutions fleeing. The most recent insider data, from March, showed the Chief Commercial Officer buying 4,475 shares at $33.50, a modest but directionally positive signal. January saw coordinated sales from the CEO, CFO, and COO at prices around $32-35 — very close to where the stock trades today — which removes some of the negative interpretation from those sales being at elevated levels.
Earnings for Q2 appear to have occurred on July 29, with results already in the market as of this note. The prior print on July 22 delivered a 6.7% one-day decline. The May conference event saw a 2.6% gain the next day and 7.4% over the following week. The next scheduled event is October 21. What to watch now is whether the earnings reaction — fresh as of today — shifts the options PCR toward puts, whether the short position begins to meaningfully reduce given the stock is back at January insider-sale levels, and whether any data readout timeline for oral Phase 3 VK2735 gets clarified on the call.
See the live data behind this article on ORTEX.
Open VKTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
